Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Viagenpumatucel-L (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Dec 2015 Number of treatment arms changed from 1 to 3, according to ClinicalTrials.gov record.
- 01 Dec 2015 Number of treatment arms changed from 1 to 3, according to ClinicalTrials.gov record.
- 16 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.